Cited by 895Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatitis Pathology and Treatment

The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.

Molecular subtypes of pancreatic cancer

Open access

Collisson, Eric A., Bailey, Peter, Chang, David K., Biankin, Andrew V.·2019·Nature Reviews Gastroenterology & Hepatology

DOI 10.1038/s41575-019-0109-y

Open this paper in CoChat — free account

Abstract

Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease.

Integrity signals

Registry

Crossref · 10.1038/s41575-019-0109-y

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Cancer Statistics, 2017.
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citation
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Self-citation

Show all 119 references

Research works printed but not linked: 1

Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 2140–2141 (2014).

Sorted by citations

Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
An Introduction to Machine Learning
Badillo, S., Bánfai, B., Birzele, F., Davydov, I. I., Hutchinson, L. G., Kam‐Thong, T., Siebourg‐Polster, J., Steiert, B., & Zhang, J. D. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1796 · Cited by 903
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Raghavan, S., Winter, P. S., Navia, A. W., Williams, H. L., DenAdel, A., Lowder, K. E., Galvez-Reyes, J., Kalekar, R. L., Mulugeta, N., Kapner, K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.017 · Cited by 592
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.023 · Cited by 578
Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W., Mohan, R., Drokhlyansky, E., Van Wittenberghe, N., Ashenberg, O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01134-8 · Cited by 426
Neoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer
O’Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S., Grant, R. C., Denroche, R. E., Zhang, A., Wang, Y., Miller, J. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3724 · Cited by 352
Cell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 344
Microenvironmental Determinants of Pancreatic Cancer
Heßmann, E., Buchholz, S., Demir, İ. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neeße, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 336
Design and Challenges of Sonodynamic Therapy System for Cancer Theranostics: From Equipment to Sensitizers
Gong, Z., & Dai, Z. (2021) · Advanced Science · doi:10.1002/advs.202002178 · Cited by 325
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró, R., Pinyol, R., Torres‐Martín, M., Bassaganyas, L., Moeini, A., Peix, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.008 · Cited by 309
Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment
Werba, G., Weissinger, D., Kawaler, E. A., Zhao, E., Kalfakakou, D., Dhara, S., Wang, L., Lim, H. B., Oh, G., Jing, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36296-4 · Cited by 303
RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions
Javid, H., Oryani, M. A., Rezagholinejad, N., Esparham, A., Tajaldini, M., & Karimi‐Shahri, M. (2024) · Cancer Medicine · doi:10.1002/cam4.6800 · Cited by 286
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
Treatment landscape of metastatic pancreatic cancer
Dosso, S. D., Siebenhüner, A. R., Winder, T., Meisel, A., Fritsch, R., Astaras, C., Szturz, P., & Borner, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102180 · Cited by 212
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt‐Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 224
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma
Hayashi, A., Fan, J., Chen, R., Ho, Y.-J., Makohon-Moore, A. P., Lecomte, N., Zhong, Y., Hong, J., Huang, J., Sakamoto, H., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0010-1 · Cited by 205
Pancreatic cancer treatment: better, but a long way to go
Torphy, R. J., Fujiwara, Y., & Schulick, R. D. (2020) · Surgery Today · doi:10.1007/s00595-020-02028-0 · Cited by 199
The RING finger protein family in health and disease
Cai, C., Tang, Y., Zhai, J., & Zheng, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01152-2 · Cited by 204
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Dreyer, S. B., Upstill‐Goddard, R., Paulus-Hock, V., Paris, C., Lampraki, E.-M., Dray, E. V., Serrels, B., Caligiuri, G., Rebus, S., Plenker, D., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.09.043 · Cited by 165
Self-citation
Basal‐like and classical cells coexist in pancreatic cancer revealed by single‐cell analysis on biopsy‐derived pancreatic cancer organoids from the classical subtype
Juiz, N. A., Kaoutari, A. E., Bigonnet, M., Gayet, O., Roques, J., Nicolle, R., Iovanna, J., & Dusetti, N. (2020) · The FASEB Journal · doi:10.1096/fj.202000363rr · Cited by 152
The PDAC extracellular matrix: a review of the ECM protein composition, tumor cell interaction, and therapeutic strategies
Perez, V. M., Kearney, J. F., & Yeh, J. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751311 · Cited by 143
Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment
Xue, M., Zhu, Y., Jiang, Y., Han, L., Shi, M., Su, R. J., Wang, L., Xiong, C., Wang, C., Wang, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40314-w · Cited by 153
Targeting ferroptosis in pancreatic cancer: a double-edged sword
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.005 · Cited by 143
The biological underpinnings of therapeutic resistance in pancreatic cancerPreprint
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 139
Spatial oncology: Translating contextual biology to the clinic
Gong, D. H., Arbesfeld-Qiu, J. M., Perrault, E. N., Bae, J. W., & Hwang, W. L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.001 · Cited by 140
Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma
Porter, R. L., Magnus, N. K. C., Thapar, V., Morris, R., Szabolcs, A., Neyaz, A., Kulkarni, A. S., Tai, E., Chougule, A., Hillis, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914915116 · Cited by 129
Elucidation of tumor-stromal heterogeneity and the ligand-receptor interactome by single-cell transcriptomics in Real-world pancreatic cancer biopsies
Lee, J. J., Bernard, V., Semaan, A., Monberg, M. E., Huang, J., Stephens, B. M., Lin, D., Rajapakshe, K. I., Weston, B. R., Bhutani, M. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3925 · Cited by 128
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Grossman, J. E., Muthuswamy, L. B., Huang, L., Akshinthala, D., Perea, S., González, R. S., Tsai, L. L., Cohen, J., Bockorny, B., Bullock, A. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4116 · Cited by 128
Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy
Krieger, T. G., Blanc, S. L., Jabs, J., Ten, F. W., Ishaque, N., Jechow, K., Debnath, O., Leonhardt, C.-S., Giri, A., Eils, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26059-4 · Cited by 128
Recent insights into the biology of pancreatic cancer
Yao, W., Maitra, A., & Ying, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102655 · Cited by 127
Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes
Miyabayashi, K., Baker, L. A., Deschênes, A., Traub, B., Caligiuri, G., Plenker, D., Alagesan, B., Belleau, P., Li, S., Kendall, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0133 · Cited by 124
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Klomp, J. A., Klomp, J. E., Stalnecker, C. A., Bryant, K. L., Edwards, A. C., Drizyte‐Miller, K., Hibshman, P. S., Diehl, J. N., Lee, Y. S., Morales, A. J., et al. (2024) · Science · doi:10.1126/science.adk0775 · Cited by 139
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer
Brunton, H., Caligiuri, G., Cunningham, R., Upstill‐Goddard, R., Bailey, U., Garner, I., Nourse, C., Dreyer, S. B., Jones, M. D., Moran‐Jones, K., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107625 · Cited by 121
Self-citation
Cell of origin influences pancreatic cancer subtype
Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H., Curtis, C., Wood, L. D., & Attardi, L. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0633 · Cited by 118
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer
Seppälä, T. T., Zimmerman, J. W., Sereni, E., Plenker, D., Suri, R., Rozich, N., Blair, A. B., Thomas, D. L., Teinor, J. A., Javed, A. A., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004200 · Cited by 119
Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer's disease progression and heterogeneity
Iturria-Medina, Y., Adewale, Q., Khan, A. F., Ducharme, S., Rosa-Neto, P., O’Donnell, K., Petyuk, V. A., Gauthier, S., De Jager, P. L., Breitner, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo6764 · Cited by 100
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
Bärthel, S., Falcomatà, C., Rad, R., Theis, F. J., & Saur, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00526-x · Cited by 105
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., Schneider, L., Muckenhuber, A., Hong, Y., Siegers, G., Nilsson, L. M., Wirth, M., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317856 · Cited by 105
SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma
Dardare, J., Witz, A., Merlin, J.-L., Gilson, P., & Harlé, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103534 · Cited by 101
Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity
Shi, X., Li, Y., Yuan, Q., Tang, S., Guo, S., Zhang, Y., He, J., Zhang, X., Han, M., Liu, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29857-6 · Cited by 103
Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review
Ruze, R., Song, J., Yin, X., Chen, Y., Xu, R., Wang, C., & Zhao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01376-w · Cited by 111
EMT and Stemness—Key Players in Pancreatic Cancer Stem Cells
Rodríguez-Aznar, E., Wiesmüller, L., Sáinz, B., & Hermann, P. C. (2019) · Cancers · doi:10.3390/cancers11081136 · Cited by 99
Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment
Shiau, C., Cao, J., Gong, D. H., Gregory, M., Caldwell, N. J., Yin, X., Cho, J.-W., Wang, P. L., Su, J., Wang, S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01890-9 · Cited by 101
Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review
Qin, J., Cheng, X., Zhang, J., & Zhang, W. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0435-2 · Cited by 94
Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting
Vaish, U., Jain, T., Are, A. C., & Dudeja, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413408 · Cited by 102
Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes
Leiphrakpam, P. D., Chowdhury, S., Zhang, M. H., Bajaj, V., Dhir, M., & Are, C. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01183-2 · Cited by 99
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
Pecoraro, C., Faggion, B., Balboni, B., Carbone, D., Peters, G. J., Diana, P., Assaraf, Y. G., & Giovannetti, E. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100779 · Cited by 92
New therapeutic targets in pancreatic cancer
Lai, E., Puzzoni, M., Ziranu, P., Pretta, A., Impera, V., Mariani, S., Liscia, N., Soro, P., Musio, F., Persano, M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101926 · Cited by 94
Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation
Somerville, T. D. D., Biffi, G., Daßler‐Plenker, J., Hur, S. K., He, X., Vance, K. E., Miyabayashi, K., Xu, Y., Maia-Silva, D., Klingbeil, O., et al. (2020) · eLife · doi:10.7554/elife.53381 · Cited by 87
Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications
Cao, L., Wu, J., Qu, X., Sheng, J., Cui, M., Liu, S., Huang, X., Xiang, Y., Li, B., Zhang, X., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01765-x · Cited by 89
Translating insights from neuropsychiatric genetics and genomics for precision psychiatry
Rees, E., & Owen, M. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00734-5 · Cited by 86
KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity
Gupta, R., Malvi, P., Parajuli, K. R., Janoštiak, R., Bugide, S., Cai, G., Zhu, L. J., Green, M. R., & Wajapeyee, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005156117 · Cited by 85
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 87
IL-17A-producing CD8 + T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts
Picard, F. S. R., Lutz, V., Brichkina, A. I., Neuhaus, F., Ruckenbrod, T., Hupfer, A., Raifer, H., Klein, M., Bopp, T., Pfefferle, P. I., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327855 · Cited by 88
Modeling pancreatic cancer in mice for experimental therapeutics
Mallya, K. B., Gautam, S. K., Aithal, A., Batra, S. K., & Jain, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188554 · Cited by 88
GREM1 is required to maintain cellular heterogeneity in pancreatic cancer
Lan, L., Evan, T., Li, H., Hussain, A., Ruiz, E. J., Thin, M. Z., Ferreira, R. M. M., Hari, P. S., Riising, E. M., Zen, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04888-7 · Cited by 84
Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma
Alonso‐Nocelo, M., Ruíz-Cañas, L., Sancho, P., Görgülü, K., Alcalá, S., Pedrero, C., Vallespinós, M., López-Gil, J. C., Ochando, M., García-García, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325564 · Cited by 86
Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
Li, Y., Tang, S., Shi, X., Lv, J., Wu, X., Zhang, Y., Wang, H., He, J., Zhu, Y., Ju, Y., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101162 · Cited by 79
Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer
Yang, H., Zhang, X., Lao, M., Sun, K., He, L., Xu, J., Duan, Y., Chen, Y., Ying, H., Li, M., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01102-z · Cited by 78
EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6
Patil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0672 · Cited by 79
Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer
Chiaro, P. D., Nacci, L., Arco, F., Brandini, S., Polletti, S., Palamidessi, A., Donati, B., Soriani, C., Gualdrini, F., Frigè, G., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.017 · Cited by 80
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy
Kaissis, G., Ziegelmayer, S., Lohöfer, F., Steiger, K., Algül, H., Muckenhuber, A., Yen, H.-Y., Rummeny, E., Friess, H., Schmid, R., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218642 · Cited by 76
Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies
Pereira, M. A., & Chio, I. I. C. (2019) · Genes · doi:10.3390/genes11010006 · Cited by 75
Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01287-7 · Cited by 81
Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways
Guo, Y., Yu, T., Zhu, H., Xiao, Y., Guo, H., Shang, L., Zheng, W., Ma, S., Liu, X., & Bai, Y. (2020) · Cell Biology and Toxicology · doi:10.1007/s10565-020-09562-0 · Cited by 74
A comprehensive review of pancreatic cancer and its therapeutic challenges
Jiang, S., Fagman, J. B., Ma, Y., Liu, J., Vihav, C., Engström, C., Liu, B., & Chen, C. (2022) · Aging · doi:10.18632/aging.204310 · Cited by 76
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
Carbone, C., Piro, G., Agostini, A., Delfino, P., Sanctis, F. D., Nasca, V., Spallotta, F., Sette, C., Martini, M., Ugel, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002876 · Cited by 70
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response
Law, H. C.-H., Lagundžin, D., Clement, E. J., Qiao, F., Wagner, Z. S., Krieger, K. L., Costanzo-Garvey, D. L., Caffrey, T. C., Grem, J. L., DiMaio, D. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1496 · Cited by 71
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Botta, G. P., Kato, S., Patel, H., Fanta, P. T., Lee, S., Okamura, R., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.150453 · Cited by 71
Mechanisms of PDAC subtype heterogeneity and therapy response
Espinet, E., Klein, L., Puré, E., & Singh, S. K. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.08.005 · Cited by 70
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
Casolino, R., Braconi, C., Malleo, G., Paiella, S., Bassi, C., Milella, M., Dreyer, S. B., Froeling, F. E. M., Chang, D. K.-F., Biankin, A. V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.013 · Cited by 68
Self-citation
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 71
Self-citation
The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma
Evan, T., Wang, V. M.-Y., & Behrens, A. (2022) · Oncogene · doi:10.1038/s41388-022-02448-x · Cited by 66
PRMT5 promotes epithelial‐mesenchymal transition via EGFR‐β‐catenin axis in pancreatic cancer cells
Ge, L., Wang, H., Xu, X., Zhou, Z., He, J., Peng, W., Du, F., Zhang, Y., Gong, A., & Xu, M. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14894 · Cited by 64
Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response
Tang, R., Xu, J., Wang, W., Meng, Q., Shao, C., Zhang, Y., Lei, Y., Zhang, Z.-F., Liu, Y., Du, Q., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101234 · Cited by 63
Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression
Xing, C., Ye, H., Wang, W., Sun, M., Zhang, J., Zhao, Z., & Jiang, G. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1671856 · Cited by 59
ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer
Somerville, T. D. D., Xu, Y., Wu, X., Maia-Silva, D., Hur, S. K., de Almeida, L. M. N., Preall, J. B., Koo, P. K., & Vakoc, C. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921484117 · Cited by 60
Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma
Jiang, L., Qin, J., Dai, Y., Zhao, S., Zhan, Q., Cui, P., Ren, L., Wang, X., Zhang, R., Gao, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02790-x · Cited by 61
Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer
Regel, I., Mayerle, J. V., & Mukund, M. U. (2020) · Cancers · doi:10.3390/cancers12041024 · Cited by 61
Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress
Tomihara, H., Carbone, F., Perelli, L., Huang, J. K.-L., Soeung, M., Rose, J. L., Robinson, F. S., Lissanu, Y., Feng, N., Takeda, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3922 · Cited by 57
De novo compartment deconvolution and weight estimation of tumor samples using DECODER
Peng, X. L., Moffitt, R. A., Torphy, R. J., Volmar, K. E., & Yeh, J. J. (2019) · Nature Communications · doi:10.1038/s41467-019-12517-7 · Cited by 57
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Li, E., Huang, X., Zhang, G., & Liang, T. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02055-w · Cited by 56
Alantolactone: A Natural Plant Extract as a Potential Therapeutic Agent for Cancer
Cai, Y., Gao, K., Peng, B., Xu, Z., Peng, J., Li, J., Chen, X., Zeng, S., Hu, K., & Yan, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.781033 · Cited by 55
Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology
Bazzichetto, C., Luchini, C., Conciatori, F., Vaccaro, V., Cello, I. D., Mattiolo, P., Falcone, I., Ferretti, G., Scarpa, A., Cognetti, F., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228841 · Cited by 58
Spatiotemporal dynamics of self-organized branching in pancreas-derived organoids
Randriamanantsoa, S., Papargyriou, A., Maurer, H. C., Peschke, K., Schuster, M., Zecchin, G., Steiger, K., Öllinger, R., Saur, D., Scheel, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32806-y · Cited by 54
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes
Hyeon, D. Y., Nam, D., Han, Y., Kim, D. K., Kim, G., Kim, D., Bae, J., Back, S., Mun, D., Madar, I. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00479-7 · Cited by 56
Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics
Topham, J. T., Karasinska, J. M., Lee, M. K. C., Csizmók, V., Williamson, L., Jang, G. H., Denroche, R. E., Tsang, E. S., Kalloger, S. E., Wong, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2831 · Cited by 54
Pre-clinical Models of Metastasis in Pancreatic Cancer
Miquel, M., Zhang, S., & Pilarsky, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748631 · Cited by 53
PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability
Pitarresi, J. R., Norgard, R. J., Chiarella, A. M., Suzuki, K., Bakir, B. S., Sahu, V., Li, J., Zhao, J., Marchand, B., Wengyn, M. D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1098 · Cited by 54
Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma
Nakaoka, K., Ohno, E., Kawabe, N., Kuzuya, T., Funasaka, K., Nakagawa, Y., Nagasaka, M., Ishikawa, T., Watanabe, A., Tochio, T., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13020215 · Cited by 53
Molecular Subtyping and Precision Medicine for Pancreatic Cancer
Froeling, F. E. M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K.-F., & Precision-Panc, O. B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010149 · Cited by 52
Self-citation
Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
Bugazia, D., Al-Najjar, E., Esmail, A., Abdelrahim, S., Abboud, K., Abdelrahim, A., Umoru, G., Rayyan, H. A., Abudayyeh, A., Moustafa, A. A., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1386699 · Cited by 51
The Intimate Relationship among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes
Hass, R., von der Ohe, J., & Ungefroren, H. (2020) · Cancers · doi:10.3390/cancers12123674 · Cited by 53
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes
Eyres, M., Lanfredini, S., Xu, H., Burns, A., Blake, A., Willenbrock, F. W., Goldin, R. D., Hughes, D. L., Hughes, S. L., Thapa, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.044 · Cited by 50
Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis
Qi, S., Guan, X., Zhang, J., Yu, D., Yu, X., Li, Q., Yin, W., Cheng, X., Zhang, W., & Qin, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01538-4 · Cited by 50
Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma
Kaissis, G. A., Ziegelmayer, S., Lohöfer, F. K., Harder, F. N., Jungmann, F., Sasse, D., Muckenhuber, A., Yen, H.-Y., Steiger, K., Siveke, J. T., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030724 · Cited by 50

Authors: Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V.
Affiliations: University of California, San Francisco (US)
University of Glasgow (GB)
Glasgow Royal Infirmary (GB)
Corresponding author: Biankin, Andrew V.
ORCID: Collisson, Eric A.
Bailey, Peter
Chang, David K.
Biankin, Andrew V.
Venue: Nature Reviews Gastroenterology & Hepatology
Publisher: Springer Science and Business Media LLC
Published: 2019-02-04
Volume: 16
Issue: 4
Pages: 207-220
ISSN: 1759-5045 (ISSN-L)
1759-5053
DOI: 10.1038/s41575-019-0109-y
OpenAlex: W2913268845
Cited by: 892
References: 119
Citations by year: 2026: 69 · 2025: 87 · 2024: 168 · 2023: 142 · 2022: 135 · 2021: 157 · 2020: 104 · 2019: 28
FWCI: 10.11
Type: journal article
Language: en
Open access: green
eprints.gla.ac.uk
Licence: cc-by-sa
www.springer.com/tdm (tdm)
Locations: Nature Reviews Gastroenterology & Hepatology (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
Funders: Pancreatic Cancer UK (FLF2015_04_GLASGOW)
Wellcome Trust (103721/Z/14/Z)
Cancer Research UK (23526, 17263)
Medical Research Council (MR/N005813/1)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords: pancreatic cancer, molecular subtypes, molecular taxonomy, molecular subtyping, therapeutic targeting, treatment response, histological classification
MeSH terms: Clinical Decision-Making, Genetic Markers, Humans, Pancreatic Neoplasms, Prognosis, Biomarkers, Tumor, Risk Assessment, Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular subtypes of pancreatic cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks